Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $143 from $135 and keeps an Overweight rating on the shares following “a beat and raise quarter” that was driven by underlying momentum in the HIV franchise. The firm, which thinks Descovy trends “bode well” for the Yeztugo outlook, raised its estimates following the quarterly report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD: